NEW YORK, Feb. 20, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKT:PXRB) and certain of its officers, on behalf of a class who purchased PixarBio securities: (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pxrb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s statements in press releases, third-party promotional materials, and its Form S-1 regarding, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and its current and prospective development efforts lacked accuracy; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
On January 23, 2017, the SEC disclosed the temporary suspension of PixarBio trading “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.”
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pxrb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 



